Alleviating the Metabolic Side Effects of Antipsychotic Medications

Exclusion Criteria

• •Aged \< 18 or \> 65 years.
• •On a Community Treatment Order (CTO).
• •Comorbid mental health conditions including schizoaffective disorder, personality disorders, eating disorders, mental retardation, pervasive developmental disorder, delirium, dementia (ie, Mini Mental State Examination \[MMSE\] \< 23), and amnesia.
• •Concurrent treatment with two or more antipsychotics (including clozapine or olanzapine) at screening.
• •Concomitant treatment with sedatives, tricyclic antidepressants, metformin, insulin or beta adrenergic blocking agents.
• •Known or suspected hypersensitivity to moxonidine.
• •Previous history of clozapine induced myocarditis.
• •Pre-existing and/or current diagnosed heart disease.
• •Comorbid medical conditions including medicated hypertension, bradycardia (heart rate \< 50 beats/min), type 1 diabetes, epilepsy, bleeding disorders, alcohol/drug dependence, infectious blood diseases, and moderate-severe renal impairment.
• •Clinically significant abnormalities on examination or laboratory testing, and clinically significant medical conditions not listed above that are serious and/or unstable.
• •Pregnant or breastfeeding women.
• •Women of childbearing potential (WOCP) who are not using medically accepted contraception (ie, intrauterine devices \[IUDs\], hormonal contraceptives \[oral, depot, patch or injectable\], and double barrier methods such as condoms or diaphragms with spermicidal gel or foam. Women who are postmenopausal (ie, amenorrhea for at least 12 consecutive months) or surgically sterile are not considered to be WOCP.
• •Sexually active men with WOCP partners who are not using medically accepted contraception.